GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).
Go here to read the rest:
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
Allschwil, Switzerland – June 3, 2024
Originally posted here:
New data with daridorexant to be presented at SLEEP 2024
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan
Link:
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) protecting a group of molecules and their ability to trigger an immune response across a wide range of cancers by detaching the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores. The molecules are the crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275.
Nicox SA Société anonyme with a registered capital of € 502,996.94
Read the original:
Number of voting rights as of May 31, 2024
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June:
Read more here:
Pharming Group to participate in June investor conferences
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves
Go here to read the rest:
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
ORION CORPORATION PRESS RELEASE 03 June 2024 at 09.30 EEST
Original post:
Orion is developing the Finnish life science industry in a unique collaboration project
Tired of looking in the mirror and seeing those unwanted signs of aging around your eyes? Forget going under the knife theres a new option that harnesses the power of your own body to achieve a brighter, more youthful appearance.
Platelet-Rich Plasma (PRP) injections are a revolutionary treatment offered at Eterna MedSpa & Laser Vein Center that can tackle a multitude of under-eye concerns.
The procedure uses a clients own blood plasma to tighten the skin and reduce wrinkles. How?
During the treatment, a small amount of blood is drawn and then placed in a centrifuge where it is spun at high speeds so the plasma rises to the top. The plasma is then drawn out into a syringe and injected in the under eye area.
The plasma contains proteins which strengthen and volumize the skin. In the under-eye area, rejuvenation occurs, stimulating the natural production of collagen, elastin, and hyaluronic acid.
The benefits of Platelet-Rich Plasma extend beyond just wrinkle reduction.
PRP helps with dark circles, puffiness, and shallowness under the eyes, said Kathe Malinowski, lead esthetician and Marketing Manager for Eterna MedSpa & Laser Vein Center. It also minimizes crepey skin under the eye area.
The results of the injections can last anywhere from six months to a year, depending on your individual age and skin condition.
Wondering if Platelet-Rich Plasma therapy is the right choice for you? Eterna MedSpa offers complimentary consultations with a nurse where you can discuss your goals and get a personalized treatment plan.
Dont wait any longer to achieve the beautiful, youthful eyes you deserve explore the power of PRP at Eterna MedSpa & Laser Vein Center.
For more information, please contact:
Eterna MedSpa & Laser Vein Center : 217 Vertin Boulevard : Shorewood, IL 60404 : 815.254.8888 : https://www.eternalaser.com/
[SPONSORED] Eterna MedSpa offers products that rejuvenate Jessica Knowles of Eterna MedSpa discusses the importance of skincare products. Injectables and other procedures provided by Eterna MedSpa will only take patients so far. Regular skin care is necessary to keep your skin looking smooth and youthful.
Original post:
PRP Under Eye Treatment: What You Should Know - The Herald-News